Ultragenyx After Setrusumab - A Cleaner Rare‑Disease Story Worth Reassessing
Ultragenyx (RARE) fell sharply after Phase III failures for setrusumab and ensuing litigation. The stock has since stabilized around $27.40. With multiple marketed products, a $2.7B market cap and an enterprise value of ~$2.53B, the company looks like a reset case where investors can buy an established rare‑disease commercial platform without the e…